![](/img/cover-not-exists.png)
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma
Lok, A., Mocquard, J., Bourcier, J., Redelsperger, L., Bonnet, A., Chauvin, C., Thomare, P., Mahe, B., Touzeau, C., Moreau, P.Volume:
99
Language:
english
Journal:
Haematologica
DOI:
10.3324/haematol.2013.100396
Date:
March, 2014
File:
PDF, 513 KB
english, 2014